Header Logo

Connection

Rami Doukky to Myocardial Perfusion Imaging

Back to Details
This is a "connection" page, showing publications Rami Doukky has written about Myocardial Perfusion Imaging.
Rami Doukky
Connection Strength
21.544
Myocardial Perfusion Imaging
  1. ASNC SPECT-MPI quality metrics: a race to the top. J Nucl Cardiol. 2023 06; 30(3):911-914.
    View in: PubMed
    Score: 0.787
  2. Impact of change of ischemic burden on the outcomes of ESRD patients awaiting kidney transplantation. J Nucl Cardiol. 2023 10; 30(5):1897-1903.
    View in: PubMed
    Score: 0.786
  3. The prognostic and diagnostic implications of surveillance serial myocardial perfusion imaging in asymptomatic renal transplant candidates. J Nucl Cardiol. 2023 02; 30(1):152-163.
    View in: PubMed
    Score: 0.739
  4. The Prognostic Value of MPI in CKD: Can we do better? J Nucl Cardiol. 2022 Feb; 29(1):155-157.
    View in: PubMed
    Score: 0.674
  5. The diagnostic and prognostic value of near-normal perfusion or borderline ischemia on stress myocardial perfusion imaging. J Nucl Cardiol. 2022 04; 29(2):826-835.
    View in: PubMed
    Score: 0.657
  6. The prognostic implications of ST-segment and T-wave abnormalities in patients undergoing regadenoson stress SPECT myocardial perfusion imaging. J Nucl Cardiol. 2022 04; 29(2):810-821.
    View in: PubMed
    Score: 0.657
  7. Ischemia and Viability Testing in New-Onset Heart Failure. Curr Cardiol Rep. 2020 07 06; 22(8):76.
    View in: PubMed
    Score: 0.646
  8. The prognostic utility of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease: The largest cohort to date. J Nucl Cardiol. 2022 Feb; 29(1):101-110.
    View in: PubMed
    Score: 0.646
  9. The prognostic value of regadenoson SPECT myocardial perfusion imaging: The largest cohort to date. J Nucl Cardiol. 2021 12; 28(6):2799-2807.
    View in: PubMed
    Score: 0.638
  10. Myocardial perfusion imaging and coronary calcium score: A marriage made in heaven. J Nucl Cardiol. 2021 10; 28(5):2097-2099.
    View in: PubMed
    Score: 0.620
  11. Assessment of myocardial viability using single-photon emission computed tomography myocardial perfusion imaging. Curr Opin Cardiol. 2019 09; 34(5):473-483.
    View in: PubMed
    Score: 0.609
  12. Prognostic value of regadenoson stress myocardial perfusion imaging in patients with left bundle branch block or ventricular paced rhythm. J Nucl Cardiol. 2021 06; 28(3):967-977.
    View in: PubMed
    Score: 0.598
  13. Dual isotope stress Tl-201 and rest Tc-99m CZT SPECT: Are we truly leveraging CZT technology? J Nucl Cardiol. 2019 08; 26(4):1280-1283.
    View in: PubMed
    Score: 0.549
  14. Deciding wisely: A case for an effective use of myocardial perfusion imaging. J Nucl Cardiol. 2018 02; 25(1):53-61.
    View in: PubMed
    Score: 0.539
  15. Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review. J Nucl Cardiol. 2018 02; 25(1):137-149.
    View in: PubMed
    Score: 0.523
  16. Validation of a clinical pathway to assess asymptomatic renal transplant candidates using myocardial perfusion imaging. J Nucl Cardiol. 2018 12; 25(6):2058-2068.
    View in: PubMed
    Score: 0.518
  17. The significance of post-stress decrease in left ventricular ejection fraction in patients undergoing regadenoson stress gated SPECT myocardial perfusion imaging. J Nucl Cardiol. 2018 08; 25(4):1313-1323.
    View in: PubMed
    Score: 0.510
  18. Impact of integrating heart rate response with perfusion imaging on the prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease. J Nucl Cardiol. 2017 10; 24(5):1666-1671.
    View in: PubMed
    Score: 0.486
  19. Impact of a regimented aminophylline administration protocol on the burden of regadenoson-induced ischemia detected by SPECT myocardial perfusion imaging. J Nucl Cardiol. 2017 10; 24(5):1571-1578.
    View in: PubMed
    Score: 0.486
  20. Impact of Appropriate Use on the Estimated Radiation Risk to Men and Women Undergoing Radionuclide Myocardial Perfusion Imaging. J Nucl Med. 2016 Aug; 57(8):1251-7.
    View in: PubMed
    Score: 0.482
  21. The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease. J Nucl Cardiol. 2017 02; 24(1):112-118.
    View in: PubMed
    Score: 0.468
  22. Appropriate use criteria for SPECT myocardial perfusion imaging: Are they appropriate for women? J Nucl Cardiol. 2016 08; 23(4):695-705.
    View in: PubMed
    Score: 0.461
  23. The prognostic value of regadenoson stress: Has the case been made? J Nucl Cardiol. 2015 Aug; 22(4):608-10.
    View in: PubMed
    Score: 0.452
  24. Impact of insurance carrier, prior authorization, and socioeconomic status on appropriate use of SPECT myocardial perfusion imaging in private community-based office practice. Clin Cardiol. 2015 May; 38(5):267-73.
    View in: PubMed
    Score: 0.451
  25. Diagnostic and prognostic significance of ischemic electrocardiographic changes with regadenoson-stress myocardial perfusion imaging. J Nucl Cardiol. 2015 Aug; 22(4):700-13.
    View in: PubMed
    Score: 0.450
  26. The significance of automatically measured transient ischemic dilation in identifying severe and extensive coronary artery disease in regadenoson, single-isotope technetium-99m myocardial perfusion SPECT. J Nucl Cardiol. 2015 Jun; 22(3):526-34.
    View in: PubMed
    Score: 0.448
  27. Prognostic implications of stress modality on mortality risk and cause of death in patients undergoing office-based SPECT myocardial perfusion imaging. J Nucl Cardiol. 2016 Apr; 23(2):202-11.
    View in: PubMed
    Score: 0.447
  28. Effective risk stratification of patients on the basis of myocardial perfusion SPECT is dependent on appropriate patient selection. Curr Cardiol Rep. 2015 Jan; 17(1):549.
    View in: PubMed
    Score: 0.441
  29. Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials. J Nucl Cardiol. 2015 Oct; 22(5):1008-18.
    View in: PubMed
    Score: 0.439
  30. Are cardiologists truly better at appropriately selecting patients for stress myocardial perfusion imaging? Int J Cardiol. 2014 Sep; 176(1):285-6.
    View in: PubMed
    Score: 0.426
  31. The impact of regimented aminophylline use on extracardiac radioisotope activity in patients undergoing regadenoson stress SPECT myocardial perfusion imaging: a substudy of the ASSUAGE trial. J Nucl Cardiol. 2014 Jun; 21(3):496-502.
    View in: PubMed
    Score: 0.414
  32. Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge. Int J Chron Obstruct Pulmon Dis. 2014; 9:129-37.
    View in: PubMed
    Score: 0.413
  33. Age and gender as predictors of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: a substudy of the ASSUAGE trial. Am J Ther. 2013 Nov-Dec; 20(6):622-9.
    View in: PubMed
    Score: 0.406
  34. Impact of appropriate use on the prognostic value of single-photon emission computed tomography myocardial perfusion imaging. Circulation. 2013 Oct 08; 128(15):1634-43.
    View in: PubMed
    Score: 0.402
  35. The prognostic value of transient ischemic dilatation with otherwise normal SPECT myocardial perfusion imaging: a cautionary note in patients with diabetes and coronary artery disease. J Nucl Cardiol. 2013 Oct; 20(5):774-84.
    View in: PubMed
    Score: 0.400
  36. The prognostic value of cardiac SPECT performed at the primary care physician's office. J Nucl Cardiol. 2013 Aug; 20(4):519-28.
    View in: PubMed
    Score: 0.388
  37. The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation. J Nucl Cardiol. 2013 Apr; 20(2):205-13.
    View in: PubMed
    Score: 0.382
  38. Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease--the ASSUAGE-CKD trial. Int J Cardiovasc Imaging. 2013 Jun; 29(5):1029-37.
    View in: PubMed
    Score: 0.382
  39. Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. "The ASSUAGE trial". J Nucl Cardiol. 2012 Jun; 19(3):448-57.
    View in: PubMed
    Score: 0.362
  40. Soft tissue attenuation patterns in stress myocardial perfusion SPECT images: a comparison between supine and upright acquisition systems. J Nucl Cardiol. 2011 Apr; 18(2):281-90.
    View in: PubMed
    Score: 0.335
  41. Quality metrics for single-photon emission computed tomography myocardial perfusion imaging: an ASNC information statement. J Nucl Cardiol. 2023 04; 30(2):864-907.
    View in: PubMed
    Score: 0.192
  42. Artificial Intelligence in Nuclear Cardiology. J Nucl Med. 2019 Aug; 60(8):1042-1043.
    View in: PubMed
    Score: 0.148
  43. Aminophylline shortage and current recommendations for reversal of vasodilator stress: an ASNC information statement endorsed by SCMR. J Cardiovasc Magn Reson. 2018 12 20; 20(1):87.
    View in: PubMed
    Score: 0.145
  44. Prognostic significance of ischemic electrocardiographic changes with regadenoson stress myocardial perfusion imaging. J Nucl Cardiol. 2020 10; 27(5):1521-1532.
    View in: PubMed
    Score: 0.142
  45. The prognostic value of heart rate response during vasodilator stress myocardial perfusion imaging in patients with end-stage renal disease undergoing renal transplantation. J Nucl Cardiol. 2019 06; 26(3):814-822.
    View in: PubMed
    Score: 0.133
  46. Prognostic value of heart rate response during regadenoson stress myocardial perfusion imaging in patients with end stage renal disease. J Nucl Cardiol. 2016 06; 23(3):560-9.
    View in: PubMed
    Score: 0.115
  47. Outcomes after inappropriate nuclear myocardial perfusion imaging: A meta-analysis. J Nucl Cardiol. 2016 08; 23(4):680-9.
    View in: PubMed
    Score: 0.115
  48. Aminophylline shortage and current recommendations for reversal of vasodilator stress: An ASNC information statement endorsed by SCMR. J Nucl Cardiol. 2019 Jun; 26(3):1007-1014.
    View in: PubMed
    Score: 0.036
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.